PORTAL DE REFERENCIA SOBRE I+D+i
EN SANIDAD ANIMAL
EN SANIDAD ANIMAL
CREA TU PERFIL
To win the Grand Prize of US $20 million, the winning vaccine will need to meet all the requirements set out in the Minimum Viable Product (MVP), and will ideally overcome all current hurdles that inhibit the safety and efficacy of current B. melitensis vaccines in developing countries.
Additional US $5 million prize opportunity for best in class:
A US $5 million prize will be available to Solvers that develop a vaccine that meets the MVP requirements and any one of the Best in Class criteria. The Best in Class prize will be open to Solvers for one year after the award of the Grand Prize.
Submit your application early: Starting on November 18, 2016, applications will be evaluated on a quarterly basis for one year for Milestone 1 Payments. This Milestone Prize of $100K will be awarded to a maximum of 10 of the best Solvers. Solvers are therefore advised to submit applications as early as possible to increase the chances of being eligible for this Phase 1 prize.
Para cualquier duda pueden contactar al siguiente correo electrónico: brucellosis_arroba_galvmed.org
Vetinnova © 2024
es
EN
